Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZBH 
Zimmer Biomet Holdings Inc (ZBH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: ZBH (1-star) is a SELL. SELL since 1 days. Simulated Profits (-6.75%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $110.54
1 Year Target Price $110.54
| 5 | Strong Buy |
| 6 | Buy |
| 16 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.27% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.76B USD | Price to earnings Ratio 23.1 | 1Y Target Price 110.54 |
Price to earnings Ratio 23.1 | 1Y Target Price 110.54 | ||
Volume (30-day avg) 29 | Beta 0.67 | 52 Weeks Range 88.77 - 113.87 | Updated Date 10/12/2025 |
52 Weeks Range 88.77 - 113.87 | Updated Date 10/12/2025 | ||
Dividends yield (FY) 0.99% | Basic EPS (TTM) 4.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.51% | Operating Margin (TTM) 19.52% |
Management Effectiveness
Return on Assets (TTM) 4.36% | Return on Equity (TTM) 6.53% |
Valuation
Trailing PE 23.1 | Forward PE 11.6 | Enterprise Value 26660778733 | Price to Sales(TTM) 2.4 |
Enterprise Value 26660778733 | Price to Sales(TTM) 2.4 | ||
Enterprise Value to Revenue 3.4 | Enterprise Value to EBITDA 11.72 | Shares Outstanding 198095984 | Shares Floating 197652249 |
Shares Outstanding 198095984 | Shares Floating 197652249 | ||
Percent Insiders 0.15 | Percent Institutions 98.89 |
Upturn AI SWOT
Zimmer Biomet Holdings Inc
Company Overview
History and Background
Zimmer Biomet was formed in 2015 through the merger of Zimmer Holdings and Biomet. Zimmer was founded in 1927. It has grown through internal development and acquisitions to become a leading player in the musculoskeletal healthcare industry.
Core Business Areas
- Americas: Sells products and services to customers primarily in the United States, Canada, and Latin America.
- Europe, Middle East and Africa (EMEA): Sells products and services to customers primarily in Europe, the Middle East, and Africa.
- Asia Pacific: Sells products and services to customers primarily in Japan, China, Australia, and other Asian countries.
Leadership and Structure
Ivan Tornos is the President and CEO. The company has a board of directors and operates through various global business units.
Top Products and Market Share
Key Offerings
- Knee Implants: Zimmer Biomet offers a wide range of knee implants for total and partial knee replacement. Competitors include Stryker, Johnson & Johnson (DePuy Synthes), and Smith & Nephew. Revenue figures for specific product lines are not publicly available but knee implants represent a significant portion of their overall revenue. Market share data is included in Market Dynamics section.
- Hip Implants: Zimmer Biomet provides hip implants for total and partial hip replacement, and revision surgeries. Competitors include Stryker, Johnson & Johnson (DePuy Synthes), and Smith & Nephew. Revenue figures for specific product lines are not publicly available but hip implants represent a significant portion of their overall revenue. Market share data is included in Market Dynamics section.
- S.E.T. Surgical, Sports Medicine, Foot & Ankle, Extremities and Trauma: The S.E.T. category covers a variety of surgical products across sports medicine, foot and ankle, extremities and trauma. Competitors vary by sub-segment but include Arthrex, Smith & Nephew, and Stryker.
- Dental Implants: Zimmer Biomet is a major player in the dental implant market. Competitors include Straumann, Nobel Biocare (Danaher), and Dentsply Sirona.
Market Dynamics
Industry Overview
The musculoskeletal healthcare industry is driven by an aging population, increasing rates of obesity, and advancements in surgical techniques and implant technology. It is highly regulated and competitive.
Positioning
Zimmer Biomet is one of the largest players in the musculoskeletal healthcare market, with a strong global presence and a comprehensive product portfolio. They compete on innovation, quality, and customer service.
Total Addressable Market (TAM)
The global orthopedics market is expected to reach hundreds of billions of dollars, with Zimmer Biomet competing for a significant share of this market. Zimmer Biometu2019s established brand, extensive product portfolio, and global reach position them well to address this TAM.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence
- Strong brand recognition
- Established relationships with surgeons and hospitals
- Extensive research and development capabilities
Weaknesses
- Product recalls and quality control issues
- Integration challenges following mergers and acquisitions
- Exposure to pricing pressures and reimbursement cuts
- Slower growth compared to some competitors in certain segments
- High debt from previous acquisitions
Opportunities
- Expanding into emerging markets
- Developing innovative new products and technologies
- Acquiring smaller companies with complementary technologies
- Increasing focus on personalized medicine and digital solutions
- Capitalizing on the growing demand for minimally invasive procedures
Threats
- Intense competition from other large orthopedic companies
- Pricing pressures from healthcare providers and payers
- Increasing regulatory scrutiny and compliance costs
- Risk of product liability lawsuits
- Economic downturns and healthcare spending cuts
Competitors and Market Share
Key Competitors
- JNJ
- SYK
- BSX
- SNY
Competitive Landscape
Zimmer Biomet faces intense competition from other large orthopedic companies, each with its own strengths and weaknesses. Zimmer Biomet competes on product innovation, quality, and customer service.
Major Acquisitions
LDR Holding Corporation
- Year: 2016
- Acquisition Price (USD millions): 1000
- Strategic Rationale: Expanded Zimmer Biomet's portfolio in the spine market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data can only be accurately retrieved from live company reports.
Future Projections: Future projections can only be accurately retrieved from live company reports and analyst estimates.
Recent Initiatives: Recent strategic initiatives include focusing on innovation, expanding into emerging markets, and improving operational efficiency.
Summary
Zimmer Biomet is a major player in the musculoskeletal healthcare market with a broad product portfolio and global presence. While the company faces competitive pressures and regulatory challenges, its strong brand and R&D capabilities position it for future growth. Management needs to focus on improving product quality and streamlining operations. Strategic acquisitions and expansion into emerging markets are key to long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zimmer Biomet Holdings Inc
Exchange NYSE | Headquaters Warsaw, IN, United States | ||
IPO Launch date 2001-07-25 | President, CEO & Chairman of the Board Mr. Ivan Tornos | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.zimmerbiomet.com |
Full time employees 17000 | Website https://www.zimmerbiomet.com | ||
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also develops surgical robot to enable placement of patient optimized orthopedic implants in the United States. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.